We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.